FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1996284435> ?p ?o ?g. }

• W1996284435 endingPage "1143" @default.
• W1996284435 startingPage "1138" @default.
• W1996284435 abstract "To study the effect of zoledronic acid on patients with pre-existing osteoporosis on androgen deprivation therapy (ADT), who are at highest risk for fracture. Zoledronic acid is a potent bisphosphonate that can prevent osteoporosis in patients with nonmetastatic (M0), prostate cancer (CaP) who are initiating ADT. The effect of zoledronic acid on patients with pre-existing osteoporosis on ADT, who are highest risk for fracture, has not been adequately studied.We enrolled 28 patients with M0 CaP on ADT with severe osteopenia or osteoporosis (baseline bone-mineral density (BMD) T score < -2.0) in this open-label, single-arm trial to assess the effect of zoledronic acid on BMD. All patients also received supplemental calcium and vitamin D, and were counseled about lifestyle modifications. Patients received zoledronic acid (4 mg) intravenously every 3 months for 4 treatments. BMD was measured by dual energy X-ray absorptiometry scan at enrollment, 6 and 12 months. Primary endpoint was percent change in lumbar spine BMD.This was a high-risk patient population-primarily older Caucasians (mean age, 73 years), former smokers, and moderate users of alcohol. Mean duration of ADT was 2.4 years. Pre-existing osteopenia or osteoporosis was observed in a single site in 9 patients and multiple sites in 19 (68%). After 12 months of zoledronic acid, lumbar spine BMD increased 4.17% (P < .0001), and BMD increased significantly (P < .05) in both hips and the right femoral neck. Seven patients (25%) experienced improved BMD into the nonosteoporotic range (T score > -2.0). Zoledronic acid infusion was well tolerated and without substantial renal toxicity.Zoledronic acid improves BMD in men with M0 CaP on ADT with severe osteopenia or osteoporosis (T scores < 2.0). This novel finding identifies a high-risk patient population that can potentially benefit from bisphosphonate therapy." @default.
• W1996284435 created "2016-06-24" @default.
• W1996284435 creator A5007767990 @default.
• W1996284435 creator A5010547832 @default.
• W1996284435 creator A5012874129 @default.
• W1996284435 creator A5034232512 @default.
• W1996284435 creator A5037368020 @default.
• W1996284435 creator A5046082288 @default.
• W1996284435 creator A5046874167 @default.
• W1996284435 creator A5054256217 @default.
• W1996284435 creator A5056636404 @default.
• W1996284435 creator A5072032751 @default.
• W1996284435 creator A5079669862 @default.
• W1996284435 creator A5081943294 @default.
• W1996284435 date "2010-05-01" @default.
• W1996284435 modified "2023-10-06" @default.
• W1996284435 title "The Use of Zoledronic Acid in Men Receiving Androgen Deprivation Therapy for Prostate Cancer With Severe Osteopenia or Osteoporosis" @default.
• W1996284435 cites W1966537328 @default.
• W1996284435 cites W1975366865 @default.
• W1996284435 cites W1977951479 @default.
• W1996284435 cites W1983351947 @default.
• W1996284435 cites W1984941837 @default.
• W1996284435 cites W1991115193 @default.
• W1996284435 cites W1993225916 @default.
• W1996284435 cites W1997732940 @default.
• W1996284435 cites W1999745335 @default.
• W1996284435 cites W2005383842 @default.
• W1996284435 cites W2007001706 @default.
• W1996284435 cites W2026455376 @default.
• W1996284435 cites W2040618631 @default.
• W1996284435 cites W2043150075 @default.
• W1996284435 cites W2070992024 @default.
• W1996284435 cites W2080960491 @default.
• W1996284435 cites W2087311324 @default.
• W1996284435 cites W2103314990 @default.
• W1996284435 cites W2107925414 @default.
• W1996284435 cites W2115441976 @default.
• W1996284435 cites W2125967305 @default.
• W1996284435 cites W2126930357 @default.
• W1996284435 cites W2146610731 @default.
• W1996284435 cites W2163830908 @default.
• W1996284435 cites W2316095838 @default.
• W1996284435 cites W2601961232 @default.
• W1996284435 cites W2793421247 @default.
• W1996284435 cites W3021926250 @default.
• W1996284435 cites W4230906021 @default.
• W1996284435 cites W4243952167 @default.
• W1996284435 cites W4254647351 @default.
• W1996284435 cites W4367435817 @default.
• W1996284435 doi "https://doi.org/10.1016/j.urology.2009.11.083" @default.
• W1996284435 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20303574" @default.
• W1996284435 hasPublicationYear "2010" @default.
• W1996284435 type Work @default.
• W1996284435 sameAs 1996284435 @default.
• W1996284435 citedByCount "31" @default.
• W1996284435 countsByYear W19962844352012 @default.
• W1996284435 countsByYear W19962844352013 @default.
• W1996284435 countsByYear W19962844352014 @default.
• W1996284435 countsByYear W19962844352015 @default.
• W1996284435 countsByYear W19962844352016 @default.
• W1996284435 countsByYear W19962844352017 @default.
• W1996284435 countsByYear W19962844352019 @default.
• W1996284435 countsByYear W19962844352021 @default.
• W1996284435 countsByYear W19962844352023 @default.
• W1996284435 crossrefType "journal-article" @default.
• W1996284435 hasAuthorship W1996284435A5007767990 @default.
• W1996284435 hasAuthorship W1996284435A5010547832 @default.
• W1996284435 hasAuthorship W1996284435A5012874129 @default.
• W1996284435 hasAuthorship W1996284435A5034232512 @default.
• W1996284435 hasAuthorship W1996284435A5037368020 @default.
• W1996284435 hasAuthorship W1996284435A5046082288 @default.
• W1996284435 hasAuthorship W1996284435A5046874167 @default.
• W1996284435 hasAuthorship W1996284435A5054256217 @default.
• W1996284435 hasAuthorship W1996284435A5056636404 @default.
• W1996284435 hasAuthorship W1996284435A5072032751 @default.
• W1996284435 hasAuthorship W1996284435A5079669862 @default.
• W1996284435 hasAuthorship W1996284435A5081943294 @default.
• W1996284435 hasConcept C121608353 @default.
• W1996284435 hasConcept C126322002 @default.
• W1996284435 hasConcept C126894567 @default.
• W1996284435 hasConcept C2775854910 @default.
• W1996284435 hasConcept C2776326535 @default.
• W1996284435 hasConcept C2776541429 @default.
• W1996284435 hasConcept C2776886416 @default.
• W1996284435 hasConcept C2777083390 @default.
• W1996284435 hasConcept C2777251235 @default.
• W1996284435 hasConcept C2777899217 @default.
• W1996284435 hasConcept C2780192828 @default.
• W1996284435 hasConcept C71924100 @default.
• W1996284435 hasConceptScore W1996284435C121608353 @default.
• W1996284435 hasConceptScore W1996284435C126322002 @default.
• W1996284435 hasConceptScore W1996284435C126894567 @default.
• W1996284435 hasConceptScore W1996284435C2775854910 @default.
• W1996284435 hasConceptScore W1996284435C2776326535 @default.
• W1996284435 hasConceptScore W1996284435C2776541429 @default.
• W1996284435 hasConceptScore W1996284435C2776886416 @default.
• W1996284435 hasConceptScore W1996284435C2777083390 @default.
• W1996284435 hasConceptScore W1996284435C2777251235 @default.

• next